Duchenne Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight | Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Solid Biosciences, Capricor, Hoffmann-La Roche, Pf

DelveInsight's "Duchenne Muscular Dystrophy - Pipeline Insight, 2026" report provides comprehensive insights about 75+ companies developing several pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Duchenne Muscular Dystrophy treatment landscape. Learn more about the evolving Duchenne Muscular Dystrophy pipeline today @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Duchenne Muscular Dystrophy Pipeline Report

• On February 17, 2026, Satellos Bioscience Inc. received IND clearance from the FDA for SAT-3247, an oral small molecule activator of AMPKβ1β2β3 complexes, enabling the initiation of a Phase I first-in-human clinical study in healthy volunteers in the United States and Canada.

• On February 10, 2026, Hoffmann-La Roche initiated a study to evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will remain in the study for approximately 264 weeks.

• On January 26, 2026, Cumberland Pharmaceuticals conducted a study with an optional open-label extension to determine the safety, pharmacokinetics, and efficacy of two doses of oral ifetroban in patients with Duchenne Muscular Dystrophy cardiomyopathy.

• On January 21, 2026, Italfarmaco conducted a study of Givinostat in all DMD patients who had been previously treated in one of the Givinostat clinical studies.

• On January 09, 2026, Santhera Pharmaceuticals initiated the Guardian protocol study to evaluate the long-term safety of vamorolone in boys with Duchenne Muscular Dystrophy, with primary focus on vertebral fractures.

• On January 02, 2026, Pfizer initiated a clinical study evaluating the safety and efficacy of gene therapy in boys diagnosed with DMD. The study follows a randomized, double-blind, placebo-controlled design.

• On December 09, 2025, Solid Biosciences announced a study to investigate the safety, tolerability, and efficacy of a single intravenous infusion of SGT-003 in participants with Duchenne muscular dystrophy across five age-defined cohorts.

• DelveInsight's Duchenne Muscular Dystrophy Pipeline Insight report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Duchenne Muscular Dystrophy treatment.

The leading Duchenne Muscular Dystrophy companies include Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd., FibroGen, Edgewise Therapeutics, Daiichi Sankyo, ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, Hoffmann-La Roche, Pfizer, REGENXBIO, Satellos Bioscience, Cumberland Pharmaceuticals, and others.

Promising Duchenne Muscular Dystrophy therapies include Vamorolone, Sevasemten 10 mg, Givinostat, DS-5141b, SGT-003, PF-06939926, NS-089/NCNP-02, RGX-202, Fordadistrogene movaparvovec, Deramiocel, Ifetroban, SAT-3247, and others.

Download for updates and the latest revolution in Duchenne Muscular Dystrophy care @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Duchenne Muscular Dystrophy Emerging Drugs Profile

Givinostat (ITF2357): Italfarmaco

Givinostat is an orally available small molecule histone deacetylase (HDAC) inhibitor developed by Italfarmaco with potential anti-inflammatory, anti-fibrotic, and muscle-regenerative properties relevant to Duchenne Muscular Dystrophy. By inhibiting HDAC enzymes, Givinostat promotes histone acetylation and modulates gene expression pathways involved in muscle cell survival, inflammation, and fibrosis. Italfarmaco is evaluating Givinostat in a Phase III clinical trial in DMD patients who have been previously treated in earlier Givinostat studies, building on an established long-term clinical evidence base for the compound across the DMD patient population.

For more information on the Duchenne Muscular Dystrophy Emerging Drugs Profile, download DelveInsight's comprehensive Duchenne Muscular Dystrophy Pipeline Insight report @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Duchenne Muscular Dystrophy Pipeline Report Provides

• Detailed insights about companies developing therapies for Duchenne Muscular Dystrophy, with aggregate therapies developed by each company.

• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Duchenne Muscular Dystrophy treatment.

• Duchenne Muscular Dystrophy companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Duchenne Muscular Dystrophy drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Duchenne Muscular Dystrophy market.

Learn more about Duchenne Muscular Dystrophy Drugs opportunities in our comprehensive Duchenne Muscular Dystrophy pipeline report @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Duchenne Muscular Dystrophy Companies

There are 75+ key companies, such as Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd., FibroGen, Edgewise Therapeutics, Daiichi Sankyo, ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, Hoffmann-La Roche, Pfizer, REGENXBIO, Satellos Bioscience, Cumberland Pharmaceuticals, and others, developing therapies for Duchenne Muscular Dystrophy, with AstraZeneca having its Duchenne Muscular Dystrophy drug candidate in the most advanced Phase III stage.

DelveInsight's Duchenne Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral

• Intravenous

• Subcutaneous

Duchenne Muscular Dystrophy products have been categorized under various Molecule types such as:

• Cell Therapy

• Peptides

• Polymer

• Small molecule

• Gene therapy

Discover the latest advancements in Duchenne Muscular Dystrophy treatment @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Duchenne Muscular Dystrophy Pipeline Report

• Coverage: Global

• Duchenne Muscular Dystrophy Companies: Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd., FibroGen, Edgewise Therapeutics, Daiichi Sankyo, ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, Hoffmann-La Roche, Pfizer, REGENXBIO, Satellos Bioscience, Cumberland Pharmaceuticals, and others.

• Duchenne Muscular Dystrophy Therapies: Vamorolone, Sevasemten 10 mg, Givinostat, DS-5141b, SGT-003, PF-06939926, NS-089/NCNP-02, RGX-202, Fordadistrogene movaparvovec, Deramiocel, Ifetroban, SAT-3247, delandistrogene moxeparvovec, and others.

• Duchenne Muscular Dystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Duchenne Muscular Dystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.